Key Highlights

● EyePoint shares have fallen sharply, most recently closing at $5.40, down 14.29%, after Duravyu missed its primary best-corrected visual acuity endpoint against Eylea at weeks 52 and 56 in a pivotal Phase 3 wet AMD trial.

● Non-inferiority was reached only through a post-hoc analysis excluding nine patients, about 4% of the Duravyu arm, who experienced vision loss the company attributed to causes unrelated to wAMD.

● Duravyu did show a durability advantage, reducing injection burden by about 42%, translating to roughly two fewer injections on average versus Eylea over the study period.

● A second, essentially identical Phase 3 trial is expected to report results in the fall of 2026, a pending catalyst that could still support an FDA filing if it produces a clean result.

EyePoint Pharmaceuticals (NASDAQ:EYPT), the Massachusetts-based developer of sustained-release therapies for retinal disease, suffered one of the more severe single-session declines in the biotech space this summer. On 17 August 2026, the company reported that its lead candidate, Duravyu, stumbled in a pivotal Phase 3 trial in wet age-related macular degeneration (wAMD), and the shares fell more than 70% on the news. The catalyst is clear and verifiable: the trial data, not sentiment or a vague market rotation, drove the collapse. What is being reassessed is the probability that Duravyu reaches the market as a differentiated competitor to established anti-VEGF therapies.

Duravyu is EyePoint's investigational sustained-delivery insert designed to release a tyrosine kinase inhibitor into the eye, with the goal of controlling wAMD while sharply reducing how often patients need injections. The Phase 3 program pitted Duravyu head-to-head against Regeneron's Eylea (aflibercept), the incumbent standard of care. In the trial that reported on 17 August, Duravyu underperformed Eylea on best-corrected visual acuity (BCVA) at weeks 52 and 56, the study's primary endpoint, meaning it did not clear the bar the company needed on the measure that matters most to regulators and physicians.

The data behind the drop

The detail that most alarmed investors concerns how EyePoint reached any claim of non-inferiority. According to the company, Duravyu met a non-inferiority threshold only through a post-hoc analysis that excluded nine patients who experienced vision loss the company attributed to causes unrelated to wAMD. Those nine patients represented roughly 4% of the approximately 211 patients in the Duravyu arm, while the Eylea arm reportedly had no comparable cases of unexplained vision loss. Chief Executive Jay Duker described the non-wAMD vision loss as "highly unusual," noting that historical rates in prior trials ran in the 3--5% range. A primary endpoint that is only salvaged by excluding patients after the fact is a materially weaker result than a clean statistical win, and the market treated it accordingly.

There was a genuinely positive strand in the readout. Duravyu demonstrated superior durability, reducing injection burden by about 42%, translating to roughly two fewer injections on average versus Eylea over the study period. Durability is the central selling point for a sustained-release insert, since reducing the frequency of intravitreal injections is a real quality-of-life benefit for patients and a differentiator against standard therapy. But durability advantages carry little weight if the therapy cannot first demonstrate that it preserves vision at least as well as the incumbent. The visual-acuity shortfall, and the unexplained vision-loss signal, overwhelmed the dosing-interval benefit in investors' eyes.

Why the reaction was so severe

For a company whose valuation rested heavily on Duravyu's prospects in wAMD, a large, competitive market, a primary-endpoint miss against the standard of care strikes at the core Investment thesis. The stock's plunge to multi-month lows reflects a repricing of approval odds and of the drug's competitive positioning even if it were approved. A therapy that is statistically behind Eylea on the key efficacy measure, and that carries an unexplained safety question around vision loss, faces a steeper regulatory path and a harder commercial sell against entrenched, well-understood anti-VEGF options.

It is important to separate confirmed fact from interpretation. Confirmed: the trial missed its BCVA primary endpoint versus Eylea at weeks 52 and 56; non-inferiority was reached only via a post-hoc analysis excluding nine patients; roughly 4% of Duravyu patients had non-wAMD vision loss versus none on Eylea; the durability benefit was about 42% fewer injections; and the stock fell more than 70% on 17 August 2026. The interpretation, that this materially lowers the odds of a clean approval and weakens Duravyu's competitive case, follows from those facts and from the market's reaction, but the ultimate regulatory outcome is not yet determined.

A second readout still looms

Crucially, the story is not over. EyePoint has run a second, essentially identical Phase 3 trial, with results expected in the fall of 2026. Some analysts have suggested that a positive readout from that companion study could still support an FDA filing, and at least one maintained a constructive view despite the sell-off, arguing the reaction may be overdone. That pending catalyst is the single most important item on EyePoint's calendar: a clean win in the second trial would meaningfully change the narrative, while a second miss would likely be decisive for the wAMD program. Investors are effectively pricing a binary event with a known date range.

The financial and strategic picture

As a clinical-stage company, EyePoint's value is tied primarily to its pipeline rather than current earnings, and the firm has continued to operate at a loss while advancing Duravyu and its other programs. The company also has commercial and legacy product Revenue and has historically funded its development through a combination of product-related income, partnerships, and Capital Markets access. A pivotal setback of this magnitude raises the practical question of financial runway and whether the company may need to raise capital on less favorable terms, particularly with the shares depressed. Beyond wAMD, EyePoint has explored Duravyu in diabetic macular edema and other retinal indications, which provides additional shots on goal but does not offset the near-term importance of the wAMD readouts.

What to watch next

The dominant catalyst is the second Phase 3 wAMD trial due in fall 2026; its primary-endpoint result versus Eylea will largely determine whether Duravyu remains a viable approval candidate in that indication. Investors will also want clarity on the unexplained vision-loss cases, whether they reflect a device-, formulation-, or chance-related issue, because a safety signal, if confirmed, could complicate approval independent of efficacy. Cash position and any financing steps are worth monitoring given the drop in the shares, as is management's commentary on regulatory strategy and on Duravyu's prospects in other retinal diseases. Wall Street's reassessment of EyePoint hinges on data still to come, not on the summer's headline alone.